International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 40

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43 R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMENDÉES (DCI Rec): Liste 40

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées.
L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 40

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas.
La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996.*

An ongoing review is under way of the long-standing objections to proposed International Nonproprietary Names (INN). As a result, objections have been withdrawn to the following names which are now included in this list of recommended INNs:

alfacalcidol, almecillin, alverine, amiflamine, anazolene sodium, calcium pantothenate, chloralose, dimepranol, elanzepine, elfazepam, esmolol, fenisorex, fibrinolysin (human), flavamine, glucosamine, iometin (131 I), iometin (125 I), leucocianidol, levocarnitine, lombazole, loprodiol, metformin, mianserin, midaflur, neocinchophen, ribavirin, ropizine, soterenol, sulmazole, thiomersal

Les objections formulées de longue date contre des Dénominations communes internationales (DCI) proposées sont examinées. Des objections ont été retirées à la suite de cet examen et les noms suivants sont donc inclus dans cette liste des DCI recommandées:

alfacalcidol, almécilline, alvérine, amiflamine, anazolene sodique, pantothénate de calcium, chloralose, diménranol, élanzépine, elfazépam, esmolol, fénisorex, fibrinolysine (humaine), flavamine, glucosamine, iométine (131 I), iométine (125 I), leucocianidol, lévocarnitine, lombazole, loprodiol, metformine, miansérine, midaflur, néocinchophène, ribavirine, ropizine, sotérénol, sulmazole, thiomersal

Se ha emprendido un examen de las objeciones que se vienen formulando desde hace tiempo a las denominaciones comunes internacionales (DCI) propuestas. Como resultado, se han retirado las objeciones a las denominaciones siguientes, que ahora están incluidas en la presente lista de DCI recomendadas:

alfacalcidol, almecilina, alverina, amiflamina, anazolene sódico, pantotenate de calcio, cloralosa, dimepranol, elanzepina, elfazepam, esmolol, fenisorex, fibrinolisina (humana), flavamine, glucosamina, iometina (131 I), iometina (125 I), leucocianidol, levocarnitin, lombazol, loprodiol, metformina, mianserina, midaflur, neocincofeno, ribavirina, ropizina, soterenol, sulmazol, tiomersal

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

abarelixum

abarelix — *N*-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-*N*-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N^6-isopropyl-L-lysyl-L-prolyl-D-alaninamide

abarélix — [*N*-acétyl-3-(naphtalén-2-yl)-D-alanyl]-(4-chloro-D-phénylalanyl)-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-(*N*-méthyl-L-tyrosyl)-D-asparaginyl-L-leucyl-[N^6-(1-méthyléthyl)-L-lysyl)-L-prolyl-D-alaninamide

abarelix — *N*-acetil-3-(2-naftil)-D-alanil-4-cloro-D-fenilalanil-3-(3-piridil)-D-alanil-L-seril-*N*-metil-L-tirosil-D-asparaginil-L-leucil-N^6-isopropil-L-lisil-L-prolil-D-alaninamida

$C_{72}H_{95}ClN_{14}O_{14}$



acidum minodronicum

minodronic acid — (1-hydroxy-2-imidazo[1,2-*a*]pyridin-3-ylethylidene)diphosphonic acid

acide minodronique — acide [1-hydroxy-2-(imidazo[**1**,2-*a*]pyridin-3-yl)éthylidène]diphosphonique

ácido minodrónico — ácido (1-hidroxi-2-imidazo[1,2-*a*]piridin-3-iletilideno)difosfónico

$C_9H_{12}N_2O_7P_2$



alfacalcidolum

alfacalcidol (5*Z*,7*E*)-9,10-secocholesta-5,7,10(19)-triene-1α,3β-diol

alfacalcidol (5*Z*,7*E*)-(1*R*,3*R*)-9,10-sécocholesta-5,7,10(19)triène-1,3-diol

alfacalcidol (5*Z*,7*E*)-9,10-secocolesta-5,7,10(19)-trieno-1α,3β-diol

$C_{27}H_{44}O_2$



almecillinum

almecillin [(allylthio)methyl]penicillin

almécilline acide (2*S*,5*R*,6*R*)-3,3-diméthyl-7-oxo-6-[[2-[(prop-2-ényl)sulfanyl]acétyl] amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylique

almecilina [(aliltio)metil]penicilina

$C_{13}H_{18}N_2O_4S_2$



alverinum

alverine *N*-ethyl-3,3'-diphenyldipropylamine

alvérine *N*-éthyl-3-phényl-*N*-(3-phénylpropyl)propan-1-amine

alverina *N*-etil-3,3'-difenildipropilamina

$C_{20}H_{27}N$



amiflaminum

amiflamine (+)-4-(dimethylamino)-α,2-dimethylphenethylamine

amiflamine (2*S*)-1-[4-(diméthylamino)-2-méthylphényl]propan-2-amine

amiflamina (+)-4-(dimetilamino)-α,2-dimetilfenetilamina

$C_{12}H_{20}N_2$



anazolenum natricum

anazolene sodium 4-[(4-anilino-5-sulfo-1-naphthyl)azo]-5-hydroxy-2,7-naphthalenedisulfonic acid, trisodium salt

anazolène sodique 4-hydroxy-5-[[4-(phénylamino)-5-sulfonatonaphtalén-1-yl]diazényl]naphtalène-2,7-disulfonate de trisodium

anazoleno sódico sal trisódica del ácido 4-[(4-anilino-5-sulfo-1-naftil)azo]-5-hidroxi-2,7-naftalenodisulfónico

$C_{26}H_{16}N_3Na_3O_{10}S_3$



atreleutonum

atreleuton 1-[(*R*)-3-[5-(*p*-fluorobenzyl)-2-thienyl]-1-methyl-2-propynyl]-1-hydroxyurea

atréleuton 1-[(1*R*)-3-[5-(4-fluorobenzyl)thiophén-2-yl]-1-méthylprop-2-ynyl]-1-hydroxyurée

atreleutón 1-[(*R*)-3-[5-(*p*-fluorobencil)-2-tienil]-1-metil-2-propinil]-1-hidroxiurea

$C_{16}H_{15}FN_2O_2S$



aviptadilum

aviptadil — L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutaminyl-L-methionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-seryl-L-isoleucyl-L-leucyl-L-asparagine

aviptadil — L-histidyl-L-séryl-L-aspartyl-L-alanyl-L-valyl-L-phénylalanyl-L-thréonyl-L-aspartyl-L-asparaginyl-L-tyrosyl-L-thréonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutaminyl-L-méthionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-séryl-L-isoleucyl-L-leucyl-L-asparagine

aviptadil — L-histidil-L-seril-L-aspartil-L-alanil-L-valil-L-fenilalanil-L-treonil-L-aspartil-L-asparaginil-L-tirosil-L-treonil-L-arginil-L-leucil-L-arginil-L-lisil-L-glutaminil-L-metionil-L-alanil-L-valil-L-fisil-L-lisil-L-tirosil-L-leucil-L-asparaginil-L-seril-L-isoleucil-L-leucil-L-asparagina

$C_{147}H_{238}N_{44}O_{42}S$

His–Ser–Asp–Ala–Val–Phe–Thr–Asp–Asn–Tyr–Thr–Arg–Leu–Arg–

Lys–Gln–Met–Ala–Val–Lys–Lys–Tyr–Leu–Asn–Ser–Ile–Leu–Asn

belaperidonum

belaperidone — (+)-3-[2-[(1*S*,5*R*,6*S*)-6-(*p*-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-2,4(1*H*,3*H*)-quinazolinedione

bélapéridone — (+)-3-[2-[(1*S*,5*R*,6*S*)-6-(4-fluorophényl)-3-azabicyclo[3.2.0]hept-3-yl]éthyl]=quinazoline-2,4(1*H*,3*H*)-dione

belaperidona — (+)-3-[2-[(1*S*,5*R*,6*S*)-6-(*p*-fluorofenil)-3-azabiciclo[3.2.0]hept-3-il]etil]-2,4(1*H*,3*H*)-quinazolinadiona

$C_{22}H_{22}FN_3O_2$



bepotastinum

bepotastine (+)-4-[[(*S*)-*p*-chloro-α-2-pyridylbenzyl]oxy]-1-piperidinebutyric acid

bépotastine acide (+)-4-[4-[(*S*)-(4-chlorophényl)(pyridin-2-yl)méthoxy]pipéridin-1-yl]butanoïque

bepotastina ácido (+)-4-[[(*S*)-*p*-cloro-α-2-piridilbencil]oxi]-1-piperidinabutírico

$C_{21}H_{25}ClN_2O_3$



bibapcitidum

bibapcitide 13,13'-[oxybis[methylene(2,5-dioxo-1,3-pyrrolidinediyl)]]bis[*N*-(mercaptoacetyl)-D-tyrosyl-*S*-(3-aminopropyl)-L-cysteinylglycyl-L-α-aspartyl-L-cysteinylglycylglycyl-*S*-(acetamidomethyl)-L-cysteinylglycyl-*S*-(acetamidomethyl)-L-cysteinylglycylglycyl-L-cysteinamide cyclic (1→5),(1'→5')-bis(sulfide)

bibapcitide (1→5),(1'→5')-bis(sulfure cyclique) du 13,13'-[oxybis[méthylène(2,5-dioxopyrrolidine-1,3-diyl)]]bis[[*N*-(sulfanylacétyl)-D-tyrosyl]-[*S*-(3-aminopropyl)-L-cystéinyl]-glycyl-L-aspartyl-L-cystéinyl-glycyl-glycyl-[*S*-[(acétylamino)méthyl]-L-cystéinyl]-glycyl-[*S*-[(acétylamino)méthyl]-L-cystéinyl]-glycyl-glycyl-L-cystéinamide]

bibapcitida (1→5),(1'→5')-bis(sulfuro cíclico) de 13,13'-[oxibis[metileno(2,5-dioxo-1,3-pirrolidinadiil)]]bis[*N*-(mercaptoacetil)-D-tirosil-*S*-(3-aminopropil)-L-cisteinilglicil-L-α-aspartil-L-cisteinilglicilglicil-*S*-(acetamidometil)-L-cisteinilglicil-*S*-(acetamidometil)-L-cisteinilglicilglicil-L-cisteinamida cíclica

$C_{112}H_{162}N_{36}O_{43}S_{10}$



biricodarum

biricodar 4-(3-pyridyl)-1-[3-(3-pyridyl)propyl]butyl (*S*)-1-[(3,4,5-trimethoxyphenyl)glyoxyloyl]pipecolate

biricodar (2*S*)-1-[2-oxo-2-(3,4,5-triméthoxyphényl)acétyl]pipéridine-2-carboxylate de 4-(pyridin-3-yl)-1-[3-(pyridin-3-yl)propyl]butyle

biricodar (*S*)-1-[(3,4,5-trimetoxifenil)glioxiloil]pipecolato de 4-(3-piridil)-1-[3-(3-piridil)propil]butilo

$C_{34}H_{41}N_3O_7$



calcii pantothenas

calcium pantothenate — calcium bis[(*R*)-*N*-(2,4-dihydroxy-3,3-dimethylbutyryl)-β-alaninate]

pantothénate de calcium — bis[3-[[(2*R*)-2,4-dihydroxy-3,3-diméthylbutanoyl]amino]propanoate] de calcium

pantotenato de calcio — bis[(*R*)-*N*-(2,4-dihidroxi-3,3-dimetilbutiril)-β-alaninato] de calcio

$C_{18}H_{32}CaN_2O_{10}$



chloralosum

chloralose — α-chloralose *or* (*R*)-1,2-*O*-(2,2,2-trichloroethylidene)-α-D-glucofuranose

chloralose — α-chloralose ou 1,2-*O*-[(1*R*)-2,2,2-trichloroéthylidène]-α-D-glucofuranose

cloralosa — α-cloralosa *o* (*R*)-1,2-*O*-(2,2,2-tricloroetilideno)-α-D-glucofuranosa

$C_8H_{11}Cl_3O_6$



declopramidum

declopramide — 4-amino-3-chloro-*N*-[2-(diethylamino)ethyl]benzamide

déclopramide — 4-amino-3-chloro-*N*-[2-(diéthylamino)éthyl]benzamide

declopramida — 4-amino-3-cloro-*N*-[2-(dietilamino)etil]benzamida

$C_{13}H_{20}ClN_3O$



denileukinum diftitoxum

denileukin diftitox — *N*-L-methionyl-387-L-histidine-388-L-alanine-1-388-toxin (*Corynebacterium diphtheriae* strain C7) (388→2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)

dénileukine diftitox — *N*-L-méthionyl[387-L-histidine-388-L-alanine]-(1-388)-toxine (souche C7 de *Corynebacterium diphtheriae*)-(388→2')-(2-133)-interleukine 2 (clone pTIL2-21a humain)

denileukina diftitox — *N*-L-metionil-387-L-histidina-388-L-alanina-1-388-toxina (cepa C7 de *Corynebacterium diphtheriae*) (388→2')-(2-133)-interleukin 2 (clon humano pTIL2-21a)

$C_{2560}H_{4036}N_{678}O_{799}S_{17}$

MGADDVVDSS KSFVMENFSS YHGTKPGYVD SIQKGIQKPK
SGTQGNYDDD WKGFYSTDNK YDAAGYSVDN ENPLSGKAGG
VVKVTYPGLT KVLALKVDNA ETIKKELGLS LTEPLMEQVG
TEEFIKRFGD GASRVVLSLP FAEGSSSVEY INNWEQAKAL
SVELEINFET RGKRGQDAMY EYMAQACAGN RVRRSVGSSL
SCINLDWDVI RDKTKTKIES LKEHGPIKNK MSESPNKTVS
EEKAKQYLEE FHQTALEHPE LSELKTVTGT NPVFAGANYA
AWAVNVAQVI DSETADNLEK TTAALSILPG IGSVMGIADG
AVHHNTEEIV AQSIALSSLM VAQAIPLVGE LVDIGFAAYN
FVESIINLFQ VVHNSYNRPA YSPGHKTHAP TSSSTKKTQL
QLEHLLLDLQ MILNGINNYK NPKLTRMLTF KFYMPKKATE
LKHLQCLEEE LKPLEEVLNL AQSKNFHLRP RDLISNINVI
VLELKGSETT FMCEYADETA TIVEFLNRWI TFCQSIISTL
T

dimepranolum

dimepranol (±)-1-(dimethylamino)-2-propanol

dimépranol (2*RS*)-1-(diméthylamino)propan-2-ol

dimepranol (±)-1-(dimetilamino)-2-propanol

$C_5H_{13}NO$



and enantiomer
et énantiomère
y enantiómero

dutasteridum

dutasteride α,α,α,α',α',α'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide

dutastéride *N*-[2,5-bis(trifluorométhyl)phényl]-3-oxo-4-aza-5α-androst-1-ène-17β-carboxamide

dutasterida α,α,α,α',α',α'-hexafluoro-3-oxo-4-aza-5α-androst-1-en-17β-carboxi-2',5'-xilidida

$C_{27}H_{30}F_6N_2O_2$



ecenofloxacinum

ecenofloxacin (+)-7-[(1*R*,5*S*,6*S*)-6-amino-1-methyl-3-azabicyclo[3.2.0]hept-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

écénofloxacine acide (+)-7-[(1*R*,5*S*,6*S*)-6-amino-1-méthyl-3-azabicyclo[3.2.0]hept-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphtyridine-3-carboxylique

ecenofloxacino ácido (+)-7-[(1*R*,5*S*,6*S*)-6-amino-1-metil-3-azabiciclo[3 2.0]hept-3-il]-1-ciclopropil-6-fluoro-1,4-dihidro-4-oxo-1,8-naftiridina-3-carboxílico

$C_{19}H_{21}FN_4O_3$



efavirenzum

efavirenz (*S*)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one

efavirenz (4*S*)-6-chloro-4-(cyclopropyléthynyl)-4-(trifluorométhyl)-1,4-dihydro-2*H*-3,1-benzoxazin-2-one

efavirenzo (*S*)-6-cloro-4-(ciclopropiletinil)-1,4-dihidro-4-(trifluorometil)-2*H*-3,1-benzoxazin-2-ona

$C_{14}H_9ClF_3NO_2$



elanzepinum

elanzepine 3-chloro-11-[3-(dimethylamino)propylidene]-5,6-dihydromorphanthridine

élanzépine 3-(3-chloro-5,6-dihydro-11*H*-dibenzo[*b,e*]azépin-11-ylidène)-*N,N*-diméthylpropan-1-amine

elanzepina 3-cloro-11-[3-(dimetilamino)propilideno]-5,6-dihidromorfantridina

$C_{19}H_{21}ClN_2$



elfazepamum

elfazepam 7-chloro-1-[2-(ethylsulfonyl)ethyl-5-(*o*-fluorophenyl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one

elfazépam 7-chloro-1-[2-(éthylsulfonyl)éthyl]-5-(2-fluorophényl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one

elfazepam 7-cloro-1-[2-(etilsulfonil)etil-5-(*o*-fluorofenil)-1,3-dihidro-2*H*-1,4-benzodiazepin-2-ona

$C_{19}H_{18}ClFN_2O_3S$



embusartanum

embusartan — methyl 6-butyl-1-[2-fluoro-4-(*o*-1*H*-tetrazol-5-ylphenyl) benzyl]-1,2-dihydro-2-oxoisonicotinate

embusartan — 6-butyl-1-[[3-fluoro-2'-(1*H*-tétrazol-5-yl)biphényl-4-yl]méthyl]-2-oxo-1,2-dihydropyridine-4-carboxylate de méthyle

embusartán — 6-butil-1-[2-fluoro-4-(*o*-1*H*-tetrazol-5-ilfenil)bencil]-1,2-dihidro-2-oxoisonicotinato de metilo

$C_{25}H_{24}FN_5O_3$



ensaculinum

ensaculin — 7-methoxy-6-[3-[4-(*o*-methoxyphenyl)-1-piperazinyl]propoxy]-3,4-dimethylcoumarin

ensaculine — 7-méthoxy-6-[3-[4-(2-méthoxyphényl)pipérazin-1-yl]propoxy]-3,4-diméthyl-2*H*-chromén-2-one

ensaculina — 7-metoxi-6-[3-[4-(*o*-metoxifenil)-1-piperazinil]propoxi]-3,4-dimetilcumarina

$C_{26}H_{32}N_2O_5$



eptifibatidum

eptifibatide — N^6-amidino-N^2-(3-mercaptopropionyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→6)-disulfide

eptifibatide — (1→6)-disulfure cyclique de [N^6-carbamimidoyl-N^2-(3-sulfanylpropanoyl)-L-lysyl]-glycyl-L-aspartyl-L-tryptophyl-L-prolyl-L-cystéinamide

eptifibatida — (1→6)-disulfuro cíclico de N^6-amidino-N^2-(3-mercaptopropionil)-L-lisilglicil-L-α-aspartil-L-triptofil-L-prolil-L-cisteinamida

$C_{35}H_{49}N_{11}O_9S_2$



esmololum

esmolol — (±)-methyl p-[2-hydroxy-(3-isopropylamino)propoxy]hydrocinnamate

esmolol — 3-[4-[(2*RS*)-2-hydroxy-3-[(1-méthyléthyl)amino]propoxy]phényl]propanoate de méthyle

esmolol — (±)-p-[2-hidroxi-(3-isopropilamino)propoxi]hidrocinamato de metilo

$C_{16}H_{25}NO_4$



and enantiomer
et énantiomère
y enantiómero

fandofloxacinum

Jofloxacin — 6-fluoro-1-(5-fluoro-2-pyridyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid

fandofloxacine — acide 6-fluoro-1-(5-fluoropyridin-2-yl)-7-(4-méthylpipérazin-1-yl)-4-oxo-1,4-dihydroquinoléine-3-carboxylique

fandofloxacino — ácido 6-fluoro-1-(5-fluoro-2-piridil)-1,4-dihidro-7-(4-metil-1-piperazinil)-4-oxo-3-quinolinacarboxílico

$C_{20}H_{18}F_2N_4O_3$



fasoracetamum

fasoracetam (+)-1-[[(*R*)-5-oxo-2-pyrrolidinyl]carbonyl]piperidine

fasoracétam (+)-1-[[(2*R*)-5-oxopyrrolidin-2-yl]carbonyl]pipéridine

fasoracetam (+)-1-[[(*R*)-5-oxo-2-pirrolidinil]carbonil]piperidina

$C_{10}H_{16}N_2O_2$



fenisorexum

fenisorex *cis*-7-fluoro-1-phenyl-3-isochromanmethylamine

fénisorex [(1*RS*,3*RS*)-7-fluoro-1-phényl-3,4-dihydro-1*H*-2-benzopyran-3-yl]méthanamine

fenisorex *cis*-1-fenil-7-fluoro-3-isocromanometilamina

$C_{16}H_{16}FNO$



and enantiomer
et énantiomère
y enantiómero

fibrinolysinum (humanum)

fibrinolysin (human) an enzyme obtained from human plasma by conversion of profibrinolysin with streptokinase to fibrinolysin

fibrinolysine (humaine) enzyme obtenue à partir de plasma humain par transformation de la profibrinolysine en fibrinolysine à l'aide de streptokinase

fibrinolisina (humana) enzima obtenida a partir del plasma humano por transformación, con estreptoquinasa, de profibrinolisina en fibrinolisina

fidarestatum

fidarestat (+)-(2*S*,4*S*)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide

fidarestat (+)-(2*S*,4*S*)-6-fluoro-2',5'-dioxo-2,3-dihydrospiro[4*H*-chromène-4,4'-imidazolidine]-2-carboxamide

fidarestat (+)-(2*S*,4*S*)-6-fluoro-2',5'-dioxoespiro[4*H*-croman-4,4'-imidazolidina]-2-carboxamida

$C_{12}H_{10}FN_3O_4$



flavaminum

flavamine 6-[(diethylamino)methyl]-3-methylflavone

flavamine 6-[(diéthylamino)méthyl]-3-méthyl-2-phényl-4*H*-chromén-4-one

flavamina 6-dietilaminometil-2-fenil-3-metil-4*H*-4-cromenona

$C_{21}H_{23}NO_2$



frovatriptanum

frovatriptan (*R*)-5,6,7,8-tetrahydro-6-(methylamino)carbazole-3-carboxamide

frovatriptan (6*R*)-6-(méthylamino)-6,7,8,9-tétrahydro-5*H*-carbazole-3-carboxamide

frovatriptán (*R*)-5,6,7,8-tetrahidro-6-(metilamino)carbazol-3-carboxamide

$C_{14}H_{17}N_3O$



fulvestrantum

fulvestrant — 7α-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17β-diol

fulvestrant — 7α-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triène-3,17β-diol

fulvestrant — 7α-[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trieno-3,17β-diol

$C_{32}H_{47}F_5O_3S$



glucosaminum

glucosamine — 2-amino-2-deoxy-β-D-glucopyranose

glucosamine — 2-amino-2-désoxy-β-D-glucopyranose

glucosamina — 2-amino-2-deoxi-β-D-glucopiranosa

$C_6H_{13}NO_5$



ibutamorenum

ibutamoren — 2-amino-*N*-[(*R*)-2-(benzyloxy)-1-[[1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl]carbonyl]ethyl]-2-methylpropionamide

ibutamoren — 2-amino-*N*-[(1*R*)-1-[(benzyloxy)méthyl]-2-[1-(méthylsulfonyl)-1,2-dihydrospiro[indole-3,4'-pipéridin]-1'-yl]-2-oxoéthyl]-2-méthylpropanamide

ibutamoreno — 2-amino-*N*-[(*R*)-2-(benciloxi)-1-[[1-(metilsulfonil)espiro[indolina-3,4'-piperidin]-1'-il]carbonil]etil]-2-metilpropionamida

$C_{27}H_{36}N_4O_5S$



iometinum (^{125}I)

iometin (^{125}I) 4-[[3-(dimethylamino)propyl]-amino]-7-[^{125}I]iodoquinoline

iométine (^{125}I) *N*-(7-[^{125}I]iodoquinoléin-4-yl)-*N,N*-diméthylpropane-1,3-diamine

iometina (^{125}I) 4-[[3-(dimetilamino)propil]-amino]-7-[^{125}I]iodoquinolina

$C_{14}H_{18}IN_3$



iometinum (^{131}I)

iometin (^{131}I) 4-[[3-(dimethylamino)propyl]-amino]-7-[^{131}I]iodoquinoline

iométine (^{131}I) *N*-(7-[^{131}I]iodoquinoléin-4-yl)-*N,N*-diméthylpropane-1,3-diamine

iometina (^{131}I) 4-[[3-(dimetilamino)propil]-amino]-7-[^{131}I]iodoquinolina

$C_{14}H_{18}IN_3$



leucocianidolum

leucocianidol 3,3',4,4',5,7-flavanhexol

leucocianidol 2-(3,4-dihydroxyphényl)-3,4-dihydro-2*H*-chroméne-3,4,5,7-tétrol

leucocianidol 3,3',4,4',5,7-flavanhexol

$C_{15}H_{14}O_7$



levocarnitinum

levocarnitine (L-3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt

lévocarnitine (3*R*)-3-hydroxy-4-(triméthylammonio)butanoate

levocarnitina hidróxido de (L-3-carboxi-2-hidroxipropil)trimetilamonio, sal interna

$C_7H_{15}NO_3$



levocetirizinum

levocetirizine [2-[4-[(*R*)-*p*-chloro-α-phenylbenzyl]-1-piperazinyl]ethoxy]acetic acid

lévocétirizine acide 2-[2-[4-[(*R*)-(4-chlorophenyl)phénylméthyl]pipérazin-1-yl]éthoxy]acétique

levocetirizina ácido [2-[4-[(*R*)-*p*-cloro-α-fenilbencil]-1-piperazinil]etoxi]acético

$C_{21}H_{25}ClN_2O_3$



levosalbutamolum

levosalbutamol (*R*)-α^1-[(*tert*-butylamino)methyl]-4-hydroxy-*m*-xylene-α,α'-diol

lévosalbutamol (1*R*)-2-[(1,1-diméthyléthyl)amino]-1-[4-hydroxy-3-(hydroxyméthyl)phényl]éthanol

levosalbutamol (*R*)-α^1-[(*terc*-butilamino)metil]-4-hidroxi-*m*-xileno-α,α'-diol

$C_{13}H_{21}NO_3$



lombazolum

lombazole (±)-1-(α-4-biphenylyl-*o*-chlorobenzyl)imidazole

lombazole 1-[(*RS*)-(biphényl-4-yl)(2-chlorophényl)méthyl]-1*H*-imidazole

lombazol (±)-1-(α-4-bifenilil-*o*-clorobencil)imidazol

$C_{22}H_{17}ClN_2$



and enantiomer
et enantiomère
y enantiómero

Ioprodiolum

Ioprodiol — 2,2-bis(chloromethyl)-1,3-propanediol

Ioprodiol — 2,2-bis(chlorométhyl)propane-1,3-diol

Ioprodiol — 2,2-bis(clorometil)-1,3-propanodiol

$C_5H_{10}Cl_2O_2$



Iotrafibanum

Iotrafiban — (*S*)-2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[4-(4-piperidyl)piperidino]carbonyl]-1*H*-1,4-benzodiazepine-2-acetic acid

Iotrafiban — acide 2-[(2*S*)-7-([4,4'-bipipéridinyl-1-yl]carbonyl)-4-méthyl-3-oxo-2,3,4,5-tétrahydro-1*H*-1,4-benzodiazépin-2-yl]acétique

Iotrafibán — ácido (*S*)-2,3,4,5-tetrahidro-4-metil-3-oxo-7-[[4-(4-piperidil)piperidino]carbonil]-1*H*-1,4-benzodiazepina-2-acético

$C_{23}H_{32}N_4O_4$



meluadrinum

meluadrine — (-)-(*R*)-α-[(*tert*-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol

méluadrine — (-)-(1*R*)-1-(2-chloro-4-hydroxyphenyl)-2-[(1,1-dimethyléthyl)amino]éthanol

meluadrina — alcohol (-)-(*R*)-α-[(*terc*-butilamino)metil]-2-cloro-4-hidroxibencílico

$C_{12}H_{18}ClNO_2$



mespiperonum (^{11}C)

mespiperone (^{11}C) 8-[3-(*p*-fluorobenzoyl)propyl]-3-[^{11}C]methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one

mespipérone (^{11}C) 8-[4-(4-fluorophényl)-4-oxobutyl]-3-[^{11}C]méthyl-1-phényl-1,3,8-triazaspiro[4.5]décan-4-one

mespiperona (^{11}C) 8-[3-(*p*-fluorobenzoil)propil]-3-[^{11}C]metil-1-fenil-1,3,8-triazaspiro[4.5]decan-4-ona

$C_{23}[^{11}C]H_{28}FN_3O_2$



metforminum

metformin 1,1-dimethylbiguanide

metformine 1,1-diméthylbiguanide

metformina 1,1-dimetilbiguanida

$C_4H_{11}N_5$



mianserinum

mianserin 1,2,3,4,10,14*b*-hexahydro-2-methyldibenzo[*c*,*f*]pyrazino[1,2-*a*]azepine

miansérine (14b*RS*)-2-méthyl-1,2,3,4,10,14b-hexahydrodibenzo[*c*,*f*]pyrazino[1,2-*a*]azépine

mianserina 1,2,3,4,10,14*b*-hexahidro-2-metildibenzo[*c*,*f*]pirazino[1,2-*a*]azepina

$C_{18}H_{20}N_2$



and enantiomer
et énantiomère
y enantiómero

midaflurum

midaflur — 4-amino-2,2,5,5-tetrakis(trifluoromethyl)-3-imidazoline

midaflur — 2,2,5,5-tétrakis(trifluorométhyl)-2,5-dihydro-1*H*-imidazol-4-amine

midaflur — 4-amino-2,2,5,5-tetrakis(trifluorometil)-3-imidazolina

$C_7H_3F_{12}N_3$



mitiglinidum

mitiglinide — (-)-(2*S*,3a,7a-*cis*)-α-benzylhexahydro-γ-oxo-2-isoindolinebutyric acid

mitiglinide — (-)-acide (2*S*)-2-benzyl-4-[(3a*R*,7a*S*)-octahydro-2*H*-isoindol-2-yl]-4-oxobutanoique

mitiglinida — ácido (-)-(2*S*,3a,7a-*cis*)-α-bencilhexahidro-γ-oxo-2-isoindolinbutírico

$C_{19}H_{25}NO_3$



moxifloxacinum

moxifloxacin — 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4a*S*,7a*S*)-octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid

moxifloxacine — acide 1-cyclopropyl-6-fluoro-8-méthoxy-7-[(4a*S*,7a*S*)-octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

moxifloxacina — ácido 1-ciclopropil-6-fluoro-1,4-dihidro-8-metoxi-7-[(4a*S*,7a*S*)-octahidro-6*H*-pirrolo[3,4-*b*]piridin-6-il]-4-oxo-3-quinolinacarboxílico

$C_{21}H_{24}FN_3O_4$



moxilubantum

moxilubant — 4-[[5-(*p*-amidinophenoxy)pentyl]oxy]-*N*,*N*-diisopropyl-3-methoxybenzamide

moxilubant — 4-[[5-(4-carbamimidoylphénoxy)pentyl]oxy]-3-méthoxy-*N*,*N*-bis(1-méthyléthyl)benzamide

moxilubant — 4-[[5-(*p*-amidinofenoxi)pentil]oxi]-*N*,*N*-diisopropil-3-metoxibenzamida

$C_{26}H_{37}N_3O_4$



neocinchophenum

neocinchophen — ethyl 6-methyl-2-phenylquinoline-4-carboxylate

néocinchophène — 6-méthyl-2-phénylquinoléine-4-carboxylate d'éthyle

neocincofeno — 2-fenil-6-metil quinolina-4-carboxilato de etilo

$C_{19}H_{17}NO_2$



nepadutantum

nepadutant — cyclo[*N*-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-L-asparaginyl-L-α-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diaminopropionyl-L-leucyl], cyclic (2→5)-peptide

népadutant — (2→5)-peptide cyclique du cyclo[[*N*^{4}-[2-(acétylamino)-2-désoxy-β-D-glucopyranosyl]-L-asparaginyl]-L-aspartyl-L-tryptophyl-L-phénylalanyl-(3-amino-L-alanyl)-L-leucyl]

nepadutant — (2→5)-péptido cíclico de ciclo[*N*-(2-acetamido-2-desoxi-β-D-glucopiranosil)-L-asparaginil-L-α-aspartil-L-triptofil-L-fenilalanil-L-2,3-diaminopropionil-L-leucil]

$C_{45}H_{58}N_{10}O_{13}$



nepafenacum

nepafenac 2-(2-amino-3-benzoylphenyl)acetamide

népafénac 2-(2-amino-3-benzoylphényl)acétamide

nepafenaco 2-(2-amino-3-benzoilfenil)acetamida

$C_{15}H_{14}N_2O_2$



nepicastatum

nepicastat 5-(aminomethyl)-1-[(*S*)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthyl]-4-imidazoline-2-thione

népicastat 5-(aminométhyl)-1-[(2*S*)-5,7-difluoro-1,2,3,4-tétrahydronaphtalén-2-yl]-1,3-dihydro-2*H*-imidazole-2-thione

nepicastat 5-(aminometil)-1-[(*S*)-5,7-difluoro-1,2,3,4-tetrahidro-2-naftil]-4-imidazolina-2-tiona

$C_{14}H_{15}F_2N_3S$



nitisinonum

nitisinone 2-(α,α,α-trifluoro-2-nitro-*p*-toluoyl)-1,3-cyclohexanedione

nitisinone 2-[2-nitro-4-(trifluorométhyl)benzoyl]cyclohexane-1,3-dione

nitisinona 2-(α,α,α-trifluoro-2-nitro-*p*-toluoil)-1,3-ciclohexanodiona

$C_{14}H_{10}F_3NO_5$



nolatrexedum

nolatrexed 2-amino-6-methyl-5-(4-pyridylthio)-4(3*H*)-quinazolinone

nolatrexed 2-amino-6-méthyl-5-[(pyridin-4-yl)sulfanyl]quinazolin-4(1*H*)-one

nolatrexed 2-amino-6-metil-5-(4-piridiltio)-4(3*H*)-quinazolinona

$C_{14}H_{12}N_4OS$



omapatrilatum

omapatrilat (4*S*,7*S*,10a*S*)-octahydro-4-[(*S*)-α-mercaptohydrocinnamamido]-5-oxo-7*H*-pyrido[2,1-*b*][1,3]thiazepine-7-carboxylic acid

omapatrilate acide (4*S*,7*S*,10a*S*)-5-oxo-4-[[(2*S*)-3-phényl-2-sulfanylpropanoyl]amino]-octahydro-7*H*-pyrido[2,1-*b*][1,3]thiazépine-7-carboxylique

omapatrilat ácido (4*S*,7*S*,10a*S*)-octahidro-4-[(*S*)-α-mercaptohidrocinamamido]-5-oxo-7*H*-pirido[2,1-*b*][1,3]tiazepina-7-carboxílico

$C_{19}H_{24}N_2O_4S_2$



pamiteplasum

pamiteplase — 275-L-glutamic acid-(1-91)-(174-527)-plasminogen activator (human tissue-type protein moiety)

pamitéplase — [275-acide L-glutamique]-(1-91)-(174-527)-activateur du plasminogène (de type tissulaire humain)

pamiteplasa — 275-ácido-L-glutámico -(1-91)-(174-527)-activador del plasminógeno (tipo tisular humano fracción proteíca)

$C_{2172}H_{3309}N_{627}O_{658}S_{34}$



* glycosylation site
* site de glycosylation
* posicion de glicosilación

paricalcitolum

paricalcitol — (7*E*,22*E*)-19-nor-9,10-secoergosta-5,7,22-triene-1α,3β,25-triol

paricalcitol — (7*E*,22*E*)-(1*R*,3*R*)-19-nor-9,10-sécoergosta-5,7,22-triéne-1,3,25-triol

paricalcitol — (7*E*,22*E*)-19-nor-9,10-secoergosta-5,7,22-trieno-1α.3β,25-triol

$C_{27}H_{44}O_3$



pemetrexedum

pemetrexed — *N*-[*p*-[2-(2-amino-4,7-dihydro-4-oxo-1*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid

pémétrexed — acide (2*S*)-2-[[4-[2-(2-amino-4-oxo-4,7-dihydro-1*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)éthyl]benzoyl]amino]pentanedioïque

pemetrexed — *ácido N*-[*p*-[2-(2-amino-4,7-dihidro-4-oxo-1*H*-pirrolo[2,3-*d*]pirimidin-5-il)etil]benzoil]-L-glutámico

$C_{20}H_{21}N_5O_6$



perflenapentum

perflenapent — dodecafluoropentane

perflénapent — dodécafluoropentane

perflenapent — dodecafluoropentano

C_5F_{12}



perflisopentum

perflisopent — nonafluoro-2-(trifluoromethyl)butane

perflisopent — nonafluoro-2-(trifluorométhyl)butane

perflisopent — nonafluoro-2-(trifluorometil)butano

C_5F_{12}



perifosinum

perifosine — 4-hydroxy-1,1-dimethylpiperidinium hydroxide, octadecyl hydrogen phosphate, inner salt

périfosine — 1,1-diméthyl-4-[[(octadécyloxy)oxydophosphoryl]oxy]pipéridinium

perifosina — 1,1-dimetil-4-[[(octadeciloxi)oxidofosforil]oxi]piperidinio

$C_{25}H_{52}NO_4P$



pexigananum

pexiganan — glycyl-L-isoleucylglycyl-L-lysyl-L-phenylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-lysyl-L-phenylalanylglycyl-L-lysyl-L-alanyl-L-phenylalanyl-L-valyl-L-lysyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysinamide

pexiganan — glycyl-L-isoleucyl-glycyl-L-lysyl-L-phénylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-lysyl-L-phénylalanyl-glycyl-L-lysyl-L-alanyl-L-phénylalanyl-L-valyl-L-lysyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysinamide

pexiganán — glicil-L-isoleucilglicil-L-lisil-L-fenilalanil-L-leucil-L-lisil-L-lisil-L-alanil-L-lisil-L-lisil-L-fenilalanilglicil-L-lisil-L-alanil-L-fenilalanil-L-valil-L-lisil-L-isoleucil-L-leucil-L-lisil-L-lisinamida

$C_{122}H_{210}N_{32}O_{22}$



pibutidinum

pibutidine — 3-amino-4-[[(*Z*)-4-[[4-(piperidinomethyl)-2-pyridyl]oxy]-2-butenyl]amino]-3-cyclobutene-1,2-dione

pibutidine — 3-amino-4-[[(2*Z*)-4-[[4-(pipéridin-1-ylméthyl)pyridin-2-yl]oxy]but-2-ényl]amino]cyclobut-3-ène-1,2-dione

pibutidina — 3-amino-4-[[(*Z*)-4-[[4-(piperidinometil)-2-piridil]oxi]-2-butenil]amino]-3-ciclobuteno-1,2-diona

$C_{19}H_{24}N_4O_3$



pregabalinum

pregabalin — (*S*)-3-(aminomethyl)-5-methylhexanoic acid

prégabaline — acide (3*S*)-3-(aminométhyl)-5-méthylhexanoïque

pregabalina — ácido (*S*)-3-(aminometil)-5-metilhexanóico

$C_8H_{17}NO_2$



prucalopridum

prucalopride — 4-amino-5-chloro-2,3-dihydro-*N*-[1-(3-methoxypropyl)-4-piperidyl]-7-benzofurancarboxamide

prucalopride — 4-amino-5-chloro-*N*-[1-(3-méthoxypropyl)pipéridin-4-yl]-2,3-dihydrobenzofurane-7-carboxamide

prucaloprida — 4-amino-5-cloro-2,3-dihidro-*N*-[1-(3-metoxipropil)-4-piperidil]-7-benzofurancarboxamida

$C_{18}H_{26}ClN_3O_3$



rapacuronii bromidum

rapacuronium bromide — 1-allyl-1-(3α,17β-dihydroxy-2β-piperidino-5α-androstan-16β-yl)piperidinium bromide, 3-acetate 17-propionate

bromure de rapacuronium — bromure de 1-[3α-(acétyloxy)-2β-(pipéridin-1-yl)-17β-(propanoyloxy)-5α-androstan-16β-yl]-1-(prop-2-ényl)pipéridinium

bromuro de rapacuronio — bromuro de 1-alil-1-(3α,17β-dihidroxi-2β-piperidino-5α-androstan-16β-il)piperidinio, 3-acetato 17-propionato

$C_{37}H_{61}BrN_2O_4$



ribavirinum

ribavirin — 1-β-D-ribofuranosyl-1*H*-1,2,4-triazole-3-carboxamide

ribavirine — 1-β-D-ribofurannosyl-1*H-1,2,4*–triazole-3-carboxamide

ribavirina — 1-β-D-ribofuranosil-1*H*-1,2,4-triazolo-3-carboxamida

$C_8H_{12}N_4O_5$



rifalazilum

rifalazil (2*S*,16*Z*,18*E*,20*S*,21*S*,22*R*,23*R*,24*R*,25*S*,26*R*,27*S*,28*E*)-5,12,21,23,25-pentahydroxy-10-(4-isobutyl-1-piperazinyl)-27-methoxy-2,4,16,20,22,24,26-heptamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)-6*H*-benzofuro[4,5-*a*]phenoxazine-1,6,15(2*H*)-trione 25-acetate

rifalazil acétate de (16*Z*,18*E*,28*E*)-(2*S*,20*S*,21*S*,22*R*,23*R*,24*R*,25*S*,26*R*,27*S*)-5,12,21,23-tétrahydroxy-27-méthoxy-2,4,16,20,22,24,26-heptaméthyl-10-[4-(2-méthylpropyl)pipérazin-1-yl]-1,6,15-trioxo-1,2-dihydro-2,7-(époxypentadéca[1,11,13]trièniмino)-6*H*-benzofuro[4,5-*a*]phénoxazin-25-yle

rifalazilo 25-acetato de (2*S*,16*Z*,18*E*,20*S*,21*S*,22*R*,23*R*,24*R*,25*S*,26*R*,27*S*,28*E*)-5,12,21,23,25-pentahidroxi-10-(4-isobutil-1-piperazinil)-27-metoxi-2,4,16,20,22,24,26-heptametil-2,7-(epoxipentadeca[1,11,13]trienimino)-6*H*-benzofuro[4,5-*a*]fenoxazina-1,6,15(2*H*)-triona

$C_{51}H_{64}N_4O_{13}$



robalzotanum

robalzotan (*R*)-3-(dicyclobutylamino)-8-fluoro-5-chromancarboxamide

robalzotan (3*R*)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2*H*-chromène-5-carboxamide

robalzotán (*R*)-3-(diciclobutilamino)-8-fluoro-5-cromancarboxamida

$C_{18}H_{23}FN_2O_2$



ropizinum

ropizine 1-(diphenylmethyl)-4-[[(6-methyl-2-pyridyl)methylene]amino]piperazine

ropizine 4-(diphénylméthyl)-*N*-[(6-méthylpyridin-2-yl)méthylène]pipérazin-1-amine

ropizina 1-(difenilmetil)-4-[[(6-metil-2-piridil)metileno]amino]piperazina

$C_{24}H_{26}N_4$



rosiglitazonum

rosiglitazone (±)-5-[*p*-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione

rosiglitazone (5*RS*)-5-[4-[2-[méthyl(pyridin-2-yl)amino]éthoxy]benzyl]thiazolidine-2,4-dione

rosiglitazona (±)-5-[*p*-[2-(metil-2-piridilamino)etoxi]bencil]-2,4-tiazolidinadiona

$C_{18}H_{19}N_3O_3S$



and enantiomer
et énantiomère
y enantiómero

seocalcitolum

seocalcitol (5*Z*,7*E*,22*E*,24*E*)-24a,26a,27a-trihomo-9,10-secocholesta-5,7,10(19),22,24-pentaene-1α,3β,25-triol

séocalcitol (5*Z*,7*E*,22*E*,24*E*)-(1*S*,3*R*)-24a,26a,27a-trihomo-9,10-sécocholesta-5,7,10(19),22,24-pentaéne-1,3,25-triol

seocalcitol (5*Z*,7*E*,22*E*,24*E*)-24a,26a,27a-trihomo-9,10-secocolesta-5,7,10(19),22,24-pentaeno-1α,3β,25-triol

$C_{30}H_{46}O_3$



silperisonum

silperisone 1-[[(*p*-fluorobenzyl)dimethylsilyl]methyl]piperidine

silpérisone 1-[[(4-fluorobenzyl)diméthylsilyl]méthyl]pipéridine

silperisona 1-[[(*p*-fluorobencil)dimetilsilil]metil]piperidina

$C_{15}H_{24}FNSi$



sinapultidum

sinapultide L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine

sinapultide L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine

sinapultida L-lisil-L-leucil-L-leucil-L-leucil-L-leucil-L-lisil-L-leucil-L-leucil-L-leucil-L-leucil-L-lisil-L-leucil-L-leucil-L-leucil-L-leucil-L-lisil-L-leucil-L-leucil-L-leucil-L-leucil-L-lisina

$C_{126}H_{238}N_{26}O_{22}$



sivelestatum

sivelestat *o*-(*p*-hydroxybenzenesulfonamido)hippuric acid, pivalate (ester)

sivélestat acide 2-[[2-[[[4-[(2,2-diméthylpropanoyl)oxy]phényl]sulfonyl]amino]benzoyl]-amino]acétique

sivelestat ácido *o*-(*p*-hidroxibencenosulfonamido)hipúrico, pivalato (éster)

$C_{20}H_{22}N_2O_7S$



soterenolum

soterenol — 2'-hydroxy-5'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonamide

sotérénol — *N*-[2-hydroxy-5-[(1*RS*)-1-hydroxy-2-[(1-méthyléthyl)amino]éthyl]phényl]-méthanesulfonamide

soterenol — 2'-hidroxi-5'-(1-hidroxi-2-isopropilaminoetil) metanosulfonanilida

$C_{12}H_{20}N_2O_4S$



and enantiomer
et énantiomère
y enantiómero

sulmazolum

sulmazole — 2-[2-methoxy-4-(methylsulfinyl)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

sulmazole — 2-[2-méthoxy-4-(méthylsulfinyl)phényl]-3*H*-imidazo[4,5-*b*]pyridine

sulmazol — 2-[2-metoxi-4-(metilsulfinil)fenil]-3*H*-imidazo[4,5-*b*]piridina

$C_{14}H_{13}N_3O_2S$



sunepitronum

sunepitron — *N*-[[(7*S*,9a*S*)-octahydro-2-(2-pyrimidinyl)-2*H*-pyrido[1,2-*a*]pyrazin-7-yl]methyl]succinimide

sunépitron — 1-[[(7*S*,9a*S*)-2-(pyrimidin-2-yl)octahydro-2*H*-pyrido[1,2-*a*]pyrazin-7-yl]méthyl]pyrrolidine-2,5-dione

sunepitrón — *N*-[[(7*S*,9a*S*)-octahidro-2-(2-pirimidinil)-2*H*-pirido[1,2-*a*]pirazin-7-il]metil]succinimida

$C_{17}H_{23}N_5O_2$



technetii (^{99m}Tc) apcitidum

technetium (^{99m}Tc) apcitide — sodium hydrogen [*N*-(mercaptoacetyl)-D-tyrosyl-*S*-(3-aminopropyl)-L-cysteinylglycyl-L-α-aspartyl-L-cysteinylglycylglycyl-*S*-(acetamidomethyl)-L-cysteinylglycyl-*S*-(acetamidomethyl)-L-cysteinylglycylglycyl-L-cysteinamide cyclic (1→5)-sulfidato(5-)-N^{11},N^{12},N^{13},S^{13}]oxo[^{99m}Tc]technetate(V)

technétium (^{99m}Tc) apcitide — hydrogéno [(1→5)-(sulfure cyclique) du [*N*-(sulfanylacétyl)-D-tyrosyl]-[*S*-(3-aminopropyl)-L-cystéinyl]-glycyl-L-aspartyl-L-cystéinyl-glycyl-glycyl-[*S*-[(acétylamino)méthyl]-L-cystéinyl]-glycyl-[*S*-[(acétylamino)méthyl]-L-cystéinyl]-glycyl-glycyl-L-cystéinamidato(5-)-N^{11},N^{12},N^{13},S^{13}]oxo[^{99m}Tc]technetate(V) de sodium

tecnecio (^{99m}Tc) apcitida — hidrógeno [*N*-(mercaptoacetil)-D-tirosil-*S*-(3-aminopropil)-L-cisteinilglicil-L-α-aspartil-L-cisteinilglicilglicil-*S*-(acetamidometil)-L-cisteinilglicil-*S*-(acetamidometil)-L-cisteinilglicilglicil-L-cisteinamida (1→5)-sulfidato cíclico (5-)-N^{11},N^{12},N^{13},S^{13}]oxo[^{99m}Tc]tecnetato(V) de sodio

$C_{51}H_{73}N_{17}NaO_{20}S_5{}^{99m}Tc$



temocaprilatum

temocaprilat — (+)-(2*S*,6*R*)-6-[[(1*S*)-1-carboxy-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5*H*)-acetic acid

témocaprilate — (+)-acide 2-[(2*S*,6*R*)-6-[[(1*S*)-1-carboxy-3-phénylpropyl]amino]-5-oxo-2-(thiophén-2-yl)tétrahydro-1,4-thiazépin-4(5*H*)-yl]acétique

temocaprilato — ácido (+)-(2*S*,6*R*)-6-[[(1*S*)-1-carboxi-3-fenilpropil]amino]tetrahidro-5-oxo-2-(2-tienil)-1,4-tiazepina-4(5*H*)-acético

$C_{21}H_{24}N_2O_5S_2$



thiomersalum

thiomersal — sodium ethylmercurithiosalicylate

thiomersal — 2-(éthylmercurisulfanyl)benzoate de sodium

tiomersal — etilmercuritiosalicilato de sodio

$C_9H_9HgNaO_2S$



thyrotropinum alfa

thyrotropin alfa — thyrotropin (human β-subunit protein moiety), complex with chorionic gonadotropin (human α-subunit protein moiety)

thyrotropine alfa — thyrotropine (humaine, partie protéique de 118 aminoacides de la sous-unité β), complexée à la gonadotropine chorionique (humaine, partie protéique de 92 aminoacides de la sous-unité α)

tirotropina alfa — tirotropina (humana,fracción proteíca de 118 aminoácidos de la subunidad β), complejado con gonadotropina coriónica (humana, fracción proteíca de 92 aminoácidos de la subunidad α)

$C_{1039}H_{1602}N_{274}O_{307}S_{27}$

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP
LRSKKTMLVQ KNVTSESTCC VAKSYNRVTV MGGFKVENHT
ACHCSTCYYH KS

FCIPTEYTMH IERRECAYCL TINTTICAGY CMTRDINGKL
FLPKYALSQD VCTYRDFIYR TVEIPGCPLH VAPYFSYPVA
LSCKCGKCNT DYSDCIHEAI KTNYCTKPQK SYLVGFSV

tifacoginum

tifacogin — *N*-L-alanylblood-coagulation factor LACI (human clone λ P9 protein moiety reduced)

tifacogine — *N*-L-alanylfacteur de coagulation sanguine LACI (partie protéique réduite produite par le clone humain λ P9)

tifacogina — N-L-alanilfactor de coagulación sanguinea LACI (fracción protéica reducida producida por el clón humano λ P9)

$C_{1400}H_{2167}N_{395}O_{422}S_{23}$

ADSEEDEEHT IITDTELPPL KLMHSFCAFK ADDGPCKAIM
KRFFFNIFTR QCEEFIYGGC EGNQNRFESL EECKKMCTRD
NANRIIKTTL QQEKPDFCFL EEDPGICRGY ITRYFYNNQT
KQCERFKYGG CLGNMNNFET LEECKNICED GPNGFQVDNY
GTQLNAVNNS LTPQSTKVPS LFEFHGPSWC LTPADRGLCR
ANENRFYYNS VIGKCRPFKY SGCGGNENNF TSKQECLRAC
KKGFIQRISK GGLIKTKRKR KKQRVKIAYE EIFVKNM

tobicillinum

tobicillin — (+)-α-hydroxy-*m*-tolyl (2*S*,5*R*,6*R*)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3 2 0]heptane-2-carboxylate, isobutyrate (ester)

tobicilline — (2*S*,5*R*,6*R*)-3,3-diméthyl-7-oxo-6-[(2-phénylacétyl)amino]-4-thia-1-azabicyclo-[3.2.0]heptane-2-carboxylate de 3-[[(2-méthylpropanoyl)oxy]méthyl]phényle

tobicillina — (2*S*,5*R*,6*R*)-3,3-dimetil-7-oxo-6-(2-fenilacetamido)-4-tia-1-azabiciclo-[3.2.0]heptano-2-carboxilato de (+)-α-hidroxi-*m*-tolilo, isobutirato (éster)

$C_{27}H_{30}N_2O_6S$



trastuzumabum

trastuzumab — immunoglobulin G 1 (human-mouse monoclonal rhuMab HER2 γ_1-chain anti-human p185$^{c\text{-}erbB2}$ receptor), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer

trastuzumab — immunoglobuline G 1 (chaîne γ_1 de l'anticorps monoclonal de souris humanisé rhuMab HER2 dirigé contre le récepteur humain p185$^{c\text{-}erbB2}$), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris humanisé rhuMab HER2

trastuzumab — inmunoglobulina G 1 (cadena γ_1 del anticuerpo monoclonal humanizado de ratón rhuMab HER2 dirigido contra el receptor humano p185$^{c\text{-}erbB2}$), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón rhuMab HER2

tremacamrum

tremacamra — 1-453-glycoprotein ICAM-1 (human reduced)

tremacamra — glycoprotéine comprenant 453 amino-acides, constituée du domaine extracellulaire de la molécule d'adhésion intracellulaire-1 humaine (ICAM-1), obtenue par génie génétique

tremacamra — 1-453-glicoproteína ICAM-1 (humana reducida)

QTSVSPSKVI LPRGGSVLVT CSTSCDQPKL LGIETPLPKK
ELLLPGNNRK VYELSNVQED SQPMCYSNCP DGQSTAKTFL
TVYWTPERVE LAPLPSWQPV GKNLTLRCQV EGGAPRANLT
VVLLRGEKEL KREPAVGEPA EVTTTVLVRR DHHGANFSCR
TELDLRPQGL ELFENTSAPY QLQTFVLPAT PPQLVSPRVL
EVDTQGTVVC SLDGLFPVSE AQVHLALGDQ RLNPTVTYGN
DSFSAKASVS VTAEDEGTQR LTCAVILGNQ SQETLQTVTI
YSFPAPNVIL TKPEVSEGTE VTVKCEAHPR AKVTLNGVPA
QPLGPRAQLL LKATPEDNGR SFSCSATLEV AGQLIHKNQT
RELRVLYGPR LDERDCPGNW TWPENSQQTP MCQAWGNPLP
ELKCLKDGTF PLPIGESVTV TRDLEGTYLC RARSTQGEVT
REVTVNVLSP RYE

valganciclovirum

valganciclovir — L-valine, ester with 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine

valganciclovir — (2*S*)-2-amino-3-méthylbutanoate de (2*RS*)-2-[(2-amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)méthoxy]-3-hydroxypropyle

valganciclovir — L-valinato de 9-[[2-hidroxi-1-(hidroximetil)etoxi]metil]guanina

$C_{14}H_{22}N_6O_5$



and epimer at C*
et l'épimère en C*
y el epímero al C*

xaliprodenum

xaliproden — 1,2,3,6-tetrahydro-1-[2-(2-naphthyl)ethyl]-4-(α,α,α-trifluoro-*m*-tolyl)pyridine

xaliprodène — 1-[2-(naphtalén-2-yl)éthyl]-4-[3-(trifluorométhyl)phényl]-1,2,3,6-tétrahydropyridine

xaliprodeno — 1,2,3,6-tetrahidro-1-[2-(2-naftil)etil]-4-(α,α,α-trifluoro-*m*-tolil)piridina

$C_{24}H_{22}F_3N$



ziconotidum

ziconotide — L-cysteinyl-L-lysylglycyl-L-lysylglycyl-L-alanyl-L-lysyl-L-cysteinyl-L-seryl-L-arginyl-L-leucyl-L-methionyl-L-tyrosyl-L-α-aspartyl-L-cysteinyl-L-cysteinyl-L-threonylglycyl-L-seryl-L-cysteinyl-L-arginyl-L-serylglycyl-L-lysyl-L-cysteinamide cyclic (1→16), (8→20), (15→25)-tris(disulfide)

ziconotide — (1→16),(8→20),(15→25)-tris(disulfure cyclique) du L-cystéinyl-L-lysyl-glycyl-L-lysyl-glycyl-L-alanyl-L-lysyl-L-cystéinyl-L-séryl-L-arginyl-L-leucyl-L-méthionyl-L-tyrosyl-L-aspartyl-L-cystéinyl-L-cystéinyl-L-thréonyl-glycyl-L-séryl-L-cystéinyl-L-arginyl-L-séryl-glycyl-L-lysyl-L-cystéinamide

ziconotida — (1→16), (8→20), (15→25)-tris(disulfuro cíclico) de L-cisteinil-L-lisilglicil-L-lisilglicil-L-alanil-L-lisil-L-cisteinil-L-seril-L-arginil-L-leucil-L-metionil-L-tirosil-L-α-aspartil-L-cisteinil-L-cisteinil-L-treonilglicil-L-seril-L-cisteinil-L-arginil-L-serilglicil-L-lisil-L-cisteinamida

$C_{102}H_{172}N_{36}O_{32}S_7$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 4
(WHO Chronicle, Vol. 16, No. 3, 1962)

p 103 **chlorprothixenum**
chlorprothixene — *replace the chemical name by the following:*
(*Z*)-3-(2-chloro-9*H*-thioxanthen-9-ylidene)-*N*,*N*,dimethylpropan-1-amine

p. 114 **chlorprothixenum**
chlorprothixène — *remplacer le nom chimique par:*
(*Z*)-3-(2-chloro-9*H*-thioxanthén-9-ylidène)-*N*,*N*,diméthylpropan-1-amine

p. 154 **chlorprothixenum**
clorporotixeno — *sustituyanse el nombre quimico por.*
(*Z*)-3-(2-cloro-9*H*-tioxanten-9-ilideno)-*N*,*N*,dimetilpropan-1-amina

Recommended International Nonproprietary Names (Rec. INN): List 5
(WHO Chronicle, Vol. 19, Nos. 4, 5, 6, 1965)

p. 9 **galantaminum**
galantamine — *replace the chemical name by the following:*
(4a*S*,6*R*,8a*S*)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro [3a,3,2-*ef*] [2] benzazepin-6-ol

Dénominations communes internationales recommendées (DCI Rec.): Liste 5
(Chronique OMS, Vol. 19, Nos. 4, 5, 6 1965)

p. 10 **galantaminum**
galantamine — *remplacer le nom chimique par le suivant:*
(4a*S*,6*R*,8a*S*)-4a,5,9,10,11,12-hexahydro-3-méthoxy-11-méthyl-6*H*-benzofuro [3a,3,2-*ef*] [2] benzazépine-6-ol

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 5
(Crónica de la OMS, Vol. 20, No. 6, 1966)

p. 259 **galantaminum**
galantamina — *sustituyase el nombre quimico por el siguiente*
(4a*S*,6*R*,8a*S*)-4a,5,9,10,11,12-hexahidro-3-metoxi-11-metil-6*H*-benzofuro [3a,3,2-*ef*] [2] benzazepina-6-ol

Recommended International Nonproprietary Names (Rec. INN): List 31
Dénominations communes internationales recommendées (DCI Rec.): Liste 31
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Liste 31
(WHO Drug Information, Vol. 5, No. 3, 1991)

p. 9 **nadroparinum calcium**
nadroparin calcium

replace the definition by the following:
Calcium salt of a low molecular mass heparin obtained by nitrous acid depolymerization of heparin from pork intestinal mucosa, followed by fractionation to eliminate selectively most of the chains with a molecular mass lower than 2000; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain; the mass-average molecular mass ranges between 3600 and 5000 with a characteristic value of about 4300; the degree of sulfatation is about 2.1 per disaccharidic unit.

p. 109 nadroparine calcique

remplacer la description par la suivante:
Sel calcique d'une héparine de basse masse moléculaire obtenue par dépolymerisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc; la majorité des composants de la nadroparine sodique possèdent une structure acide 2-*O*-sulfo-α-L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-*O*-sulfo-2,5-anhydro-D-mannitol à l'extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 3600 à 5000, avec une valeur caractéristique de 4300 environ; le degré de sulfatation est 2.1 environ par unité disaccharidique.

p. 110 nadroparina cálcica

sustituyase la descripción por la siguiente:
Sal cálcica de una heparina de baja masa molecular obtenida por despolimerización con ácido nitroso de la heparina de la mucosa intestinal de cerdo seguida de fraccionamiento a fin de eliminar selectivamente la mayor parte de las cadenas de masa molecular inferior a 2000; la mayoria de los componentes tienen una estructura de ácido 2-O-sulfo-α-L-idopiranosurónico en el extremo no reductor y una estructura de 6-*O*-sulfo-2,5-anhidro-D-manitol en el extremo reductor de la cadena; la masa molecular relativa media es de 3600 a 5000, con un valor caracteristico de 4300 aproximadamente; el grado de sulfatación es de 2.1 por unidad de disacárido.

Recommended International Nonproprietary Names (Rec. INN): List 35
Dénominations communes internationales recommendées (DCI Rec.): Liste 35
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Liste 35
(WHO Drug Information, Vol. 9, No. 3, 1995)

p. 8	*delete/supprimer/suprimase*	*insert/insérer/insértese*
	dacliximabum	daclizumabum
	dacliximab	daclizumab
	dacliximab	daclizumab
	dacliximab	daclizumab

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 38
(WHO Drug Information, Vol. 11, No. 3, 1997)

p. 174	*suprimase*	*insértese*
	omiloxetino	omiloxetina

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

Printed in Malta
97/11900 - Interprint - 5300